Article
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Blood advances - 14 Jan 2020
Ishikawa Yuichi, Kawashima Naomi, Atsuta Yoshiko, Sugiura Isamu, Sawa Masashi, Dobashi Nobuaki, Yokoyama Hisayuki, Doki Noriko, Tomita Akihiro, Kiguchi Toru, Koh Shiro, Kanamori Heiwa, Iriyama Noriyoshi, Kohno Akio, Moriuchi Yukiyoshi, Asada Noboru, Hirano Daiki, Togitani Kazuto, Sakura Toru, Hagihara Maki, Tomikawa Tatsuki, Yokoyama Yasuhisa, Asou Norio, Ohtake Shigeki, Matsumura Itaru, Miyazaki Yasushi, Naoe Tomoki, Kiyoi Hitoshi
Abstract excerpt
The prognostic impact of KIT mutation on core-binding factor acute myeloid leukemia (CBF-AML) remains controversial. We registered 199 newly diagnosed de novo CBF-AML patients, aged 16 to 64 years, who achieved complete remission. They received 3 courses of high-dose cytarabine therapy and no further treatment until hematological relapse. Mutations in exons 8, 10-11, and 17 of the KIT gene were analyzed....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.